环孢菌素A对脑细胞移植治疗大鼠实验性脑出血免疫反应的影响

Effect of Cyclosporine A on the immunoligical reject reaction of brain cell transplantation in rats with experimental brain hemorrhage

目的观察转基因细胞移植治疗大鼠实验性脑出血免疫排斥反应及环孢菌素A对其的影响。方法建立大鼠脑出血模型,采用神经生长因子(NGF)基因修饰的胶质细胞移植治疗后随机分为环孢菌素A组(A组)和未治疗组(B组)。15d后抽取外周血,用流式细胞仪进行CD+4、CD+8T淋巴细胞计数检测,免疫组化SP染色法观察移植区T细胞亚群浸润情况及组织相容性抗原复合物(MHC)Ⅱ类抗原表达情况。结果A组外周血CD+4、CD+8T淋巴细胞计数及CD+4/CD+8分别为29.20±3.97、20.65±2.02、1.41±0.86,B组分别为47.39±3.01、28.30±2.36、1.68±0.69,两组间差异有显著性(均P<0.05);免疫组化观察移植区移植物的存活率A组明显较B组高,A组CD+4、CD+8T淋巴细胞、MHCⅡ抗原积分光密度值分别为1.55±0.38、1.24±0.33、0.98±0.24,B组分别为3.33±0.37、2.64±0.56、0.86±0.22,两组间比较差异有显著性(均P<0.05)。结论脑组织内细胞移植存在免疫反应,应用免疫抑制剂可增加移植物的存活。

Objective To observe the effect of Cyclosporine A on the brain immunoligical reject reaction of transgenic cellular transplant in rats with experimental brain hemorrhage. Methods We established the brain hemorrhagic models of rats and the models were divided into group A （treated with Cyclosporin A） and group B （without treatment） randomly after transplanting brain cells modified by NGF gene. The levels of CD4^＋ , CD8^＋ T cells subsets in peripheral blood were examined by using flow cytometry at 15 d after transplantation. The expressions of MHC-class Ⅱ antigens and infiltration of CD^4, CD8^＋ T lymphocyte subsets were examined by SP immunocytochemical stain. Results The count of CD4^＋ , CD8^＋ T lymphocyte and CD4^＋/CD8^＋ in peripheral blood were 29.20 ± 3.97, 20.65±2.02 and 1.41±0.86 in group A, and were 47.39±3.01, 28.30 ±2.36 and 1.68 ± 0.69 in group B, respectively. There were significant differences between the two groups （ all P 〈 0. 05 ）. The survival rate of implant in group A was higher than in group B. Both subsets of CD4^＋ , CD8^＋ T-cells and integrated optical density （IOD） of MHC-class Ⅱ antigens and were 1.55 ±0.38, 1.24 ±0.33,0.98±0.24 in group A and 3.33 ±0.37, 2.64±0.56, 0.86± 0.22 in group B, respectively. There were significant differences between the two groups （ all P 〈 0. 05 ）. Conclusion There is immunity reject reaction of brain cell transplantation and immunosuppressant therapy may improve the livability of the implant.